Hong Kong SAR
-
The firm has poached two senior loans bankers from CMB Wing Lung -
Chinese biopharma firm parks over 70% of the IPO with cornerstones
-
The firm priced its share at HK$158, with the top 15 investors taking around 70% of the offer
-
-
Grey areas remain over changes to DCM and ECM bookbuilding
-
The $675m deal ticked many boxes for both the issuer and investors and could signal a rebound in appetite
-
-
The appointments are in the bank’s capital markets businesses in the regions
-
Chinese homebuilder has lost its investment grade ratings from all three global rating firms
-
The expanded probe brings Chinese developer’s property services unit under the regulator’s fold
-
Delisting plans 'unsurprising' as US and China remain in stalemate on key auditing requirements
-
Hong Kong's largest IPO of the year is anchored by nine cornerstone investors
